Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055419 · ClinicalTrials.gov registry record · Phase 2
A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 744
- Enrollment target
NCT00055419 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 744 participants.
The verdict
NCT00055419, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 744 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn about the safety of cetuximab in patients with stage IV colorectal cancer, and who may benefit from cetuximab.
Interventions
- BIOLOGICAL Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 744 participants |
| Start Date | 2003-02 |
| Est. Completion | 2004-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055419
The ClinicalTrials.gov registry entry for NCT00055419 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 744 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cetuximab is the first listed.
NCT00055419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00055419 about?
NCT00055419 is a clinical study titled "A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer". The purpose of this clinical research study is to learn about the safety of cetuximab in patients with stage IV colorectal cancer, and who may benefit from cetuximab.
What is the current status of trial NCT00055419?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 744 participants. The study started on 2003-02. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00055419?
The interventions under investigation include: Cetuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00055419?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.